speculative

AGEN Stock Analysis: ASCO Hype, Cash Risk

by
AGEN stock analysis featured image with market cap, revenue, and ASCO catalyst

Agenus is a real biotech catalyst trade, not a hidden value stock. At roughly a $144 million market cap, with Phase 2 melanoma data due at ASCO on May 31 and a first-quarter corporate update scheduled for May 11, the setup is obvious: if the botensilimab story keeps getting cleaner, the stock can move fast. …

Read more

QUCY (Formerly MYNZ): The Pancreatic Cancer Screening Story That Just Got Complicated

by

Ticker: NASDAQ: QUCY (formerly MYNZ) | Sector: Molecular Diagnostics / Biotech | Market Cap: Micro-cap Disclosure: This article is for informational purposes only and does not constitute investment advice. The author holds no position in QUCY/MYNZ. Small-cap biotech stocks carry extreme risk. Always conduct your own due diligence. There’s an interesting story buried inside what …

Read more